Switch theme
Sign up to access all valuation multiples
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.
2016
n/a
LTM Revenue $57.3M
LTM EBITDA -$10.9M
$2.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ABL Bio has a last 12-month revenue (LTM) of $57.3M and a last 12-month EBITDA of -$10.9M.
In the most recent fiscal year, ABL Bio achieved revenue of $24.3M and an EBITDA of -$38.6M.
ABL Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ABL Bio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $57.3M | XXX | $24.3M | XXX | XXX | XXX |
| Gross Profit | $57.3M | XXX | $24.3M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | -$10.9M | XXX | -$38.6M | XXX | XXX | XXX |
| EBITDA Margin | -19% | XXX | -159% | XXX | XXX | XXX |
| EBIT | -$12.5M | XXX | -$43.1M | XXX | XXX | XXX |
| EBIT Margin | -22% | XXX | -178% | XXX | XXX | XXX |
| Net Profit | -$10.7M | XXX | -$40.4M | XXX | XXX | XXX |
| Net Margin | -19% | XXX | -166% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ABL Bio's stock price is KRW 80600 (or $59).
ABL Bio has current market cap of KRW 3.87T (or $2.8B), and EV of KRW 3.81T (or $2.8B).
See ABL Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.8B | $2.8B | XXX | XXX | XXX | XXX | $-0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ABL Bio has market cap of $2.8B and EV of $2.8B.
ABL Bio's trades at 114.1x EV/Revenue multiple, and -71.8x EV/EBITDA.
Equity research analysts estimate ABL Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ABL Bio has a P/E ratio of -263.3x.
See valuation multiples for ABL Bio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV/Revenue | 48.3x | XXX | 114.1x | XXX | XXX | XXX |
| EV/EBITDA | -254.7x | XXX | -71.8x | XXX | XXX | XXX |
| EV/EBIT | -221.8x | XXX | -64.2x | XXX | XXX | XXX |
| EV/Gross Profit | 48.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -263.3x | XXX | -69.7x | XXX | XXX | XXX |
| EV/FCF | -136.3x | XXX | -48.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialABL Bio's last 12 month revenue growth is 53%
ABL Bio's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
ABL Bio's rule of 40 is 56% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ABL Bio's rule of X is 113% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ABL Bio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 53% | XXX | 62% | XXX | XXX | XXX |
| EBITDA Margin | -19% | XXX | -159% | XXX | XXX | XXX |
| EBITDA Growth | -240% | XXX | 362% | XXX | XXX | XXX |
| Rule of 40 | 56% | XXX | -106% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 113% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 222% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 278% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ABL Bio acquired XXX companies to date.
Last acquisition by ABL Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . ABL Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ABL Bio founded? | ABL Bio was founded in 2016. |
| Where is ABL Bio headquartered? | ABL Bio is headquartered in South Korea. |
| Who is the CEO of ABL Bio? | ABL Bio's CEO is Mr. Sang-hoon Lee. |
| Is ABL Bio publicy listed? | Yes, ABL Bio is a public company listed on KRX. |
| What is the stock symbol of ABL Bio? | ABL Bio trades under 298380 ticker. |
| When did ABL Bio go public? | ABL Bio went public in 2018. |
| Who are competitors of ABL Bio? | Similar companies to ABL Bio include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of ABL Bio? | ABL Bio's current market cap is $2.8B |
| What is the current revenue of ABL Bio? | ABL Bio's last 12 months revenue is $57.3M. |
| What is the current revenue growth of ABL Bio? | ABL Bio revenue growth (NTM/LTM) is 53%. |
| What is the current EV/Revenue multiple of ABL Bio? | Current revenue multiple of ABL Bio is 48.3x. |
| Is ABL Bio profitable? | Yes, ABL Bio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ABL Bio? | ABL Bio's last 12 months EBITDA is -$10.9M. |
| What is ABL Bio's EBITDA margin? | ABL Bio's last 12 months EBITDA margin is -19%. |
| What is the current EV/EBITDA multiple of ABL Bio? | Current EBITDA multiple of ABL Bio is -254.7x. |
| What is the current FCF of ABL Bio? | ABL Bio's last 12 months FCF is -$20.3M. |
| What is ABL Bio's FCF margin? | ABL Bio's last 12 months FCF margin is -35%. |
| What is the current EV/FCF multiple of ABL Bio? | Current FCF multiple of ABL Bio is -136.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
